annb0t
Top 20
CSL's HEMGENIX® is a one-time, single dose treatment for adults with hemophilia B who require routine prophylaxis
OTTAWA, ON, Oct. 26, 2023 /PRNewswire/ -- Global biotechnology leader CSL (ASX: CSL) today announced that Health Canada has authorized HEMGENIX® (etranacogene dezaparvovec), the first and only gene therapy for the treatment of hemophilia B. HEMGENIX is indicated for the treatment of adults with hemophilia B who require routine prophylaxis to prevent or reduce the frequency of ...
>>> Read more: Health Canada Authorizes CSL's HEMGENIX® (etranacogene dezaparvovec) as First Gene Therapy for Hemophilia B
OTTAWA, ON, Oct. 26, 2023 /PRNewswire/ -- Global biotechnology leader CSL (ASX: CSL) today announced that Health Canada has authorized HEMGENIX® (etranacogene dezaparvovec), the first and only gene therapy for the treatment of hemophilia B. HEMGENIX is indicated for the treatment of adults with hemophilia B who require routine prophylaxis to prevent or reduce the frequency of ...
>>> Read more: Health Canada Authorizes CSL's HEMGENIX® (etranacogene dezaparvovec) as First Gene Therapy for Hemophilia B
